Alaunos Therapeutics, Inc. (TCRT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 1M 2M 3M Q1 '12: 200K Q2 '12: 200K Q3 '12: 200K Q4 '12: 200K Q1 '13: 200K Q2 '13: 200K Q3 '13: 200K Q4 '13: 200K Q1 '17: 1.6M Q2 '17: 1.6M Q3 '17: 1.6M Q4 '17: 1.6M Q1 '18: 146K Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q3 '21: 398K Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 2.9M Q4 '22: 11K Q1 '23: 0 Q2 '23: 4K Q3 '23: 0 Q4 '23: 1K Q1 '24: 1K Q2 '24: 4K Q3 '24: 0 Q4 '24: 4K Q1 '25: 2K Q2 '25: 0 Q3 '25: 0 Q4 '25: 3K Q1 '26: 0 Q2 '26: 0 Q1 '13 Q2 '17 Q3 '18 Q4 '20 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-24M -16M -8M 0 8M 16M 24M Q3 '16: -10.9M Q4 '16: -11.1M Q1 '17: -14M Q2 '17: -13M Q3 '17: -13.1M Q4 '17: -13.4M Q1 '18: -16.2M Q2 '18: -12.4M Q3 '18: -12.6M Q4 '18: -12.8M Q1 '19: -13.6M Q2 '19: -14.8M Q3 '19: -13.4M Q4 '19: -16M Q1 '20: -18.7M Q2 '20: -18.6M Q3 '20: -20.3M Q4 '20: -22.8M Q1 '21: -21.6M Q2 '21: -22.6M Q3 '21: -22.3M Q4 '21: -11.1M Q1 '22: -9.1M Q2 '22: -9.2M Q3 '22: -8.3M Q4 '22: -8.5M Q1 '23: -9.7M Q2 '23: -8M Q3 '23: -8.7M Q4 '23: -7.9M Q1 '24: -1.7M Q2 '24: -1.2M Q3 '24: -1.1M Q4 '24: -755K Q1 '25: -1.1M Q2 '25: -1M Q3 '25: -1.2M Q4 '25: -907K Q1 '26: -1M Q2 '26: -952K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-140M -70M 0 70M 140M 210M Q3 '16: -10.9M Q4 '16: -14.8M Q1 '17: -15.5M Q2 '17: -12.9M Q3 '17: -12.7M Q4 '17: -18.3M Q1 '18: -16M Q2 '18: -12M Q3 '18: -12.6M Q4 '18: 194.5M Q1 '19: -13.4M Q2 '19: -14.6M Q3 '19: -74M Q4 '19: -15.7M Q1 '20: -18.3M Q2 '20: -18.6M Q3 '20: -20.3M Q4 '20: -22.8M Q1 '21: -21.6M Q2 '21: -22.7M Q3 '21: -22.7M Q4 '21: -11.8M Q1 '22: -9.8M Q2 '22: -9.9M Q3 '22: -8.9M Q4 '22: -9.2M Q1 '23: -10M Q2 '23: -8.8M Q3 '23: -8.5M Q4 '23: 22.6M Q1 '24: -1.7M Q2 '24: -1.1M Q3 '24: -1.1M Q4 '24: -742K Q1 '25: -1.1M Q2 '25: -1.1M Q3 '25: -1.2M Q4 '25: -893K Q1 '26: -1M Q2 '26: -952K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-24M -16M -8M 0 8M 16M 24M Q3 '16: -14.1M Q4 '16: -13.1M Q1 '17: -14.3M Q2 '17: -15.5M Q3 '17: -12.7M Q4 '17: -12.2M Q1 '18: -19M Q2 '18: -10.2M Q3 '18: -8.5M Q4 '18: -11.8M Q1 '19: -10.2M Q2 '19: -8.1M Q3 '19: -10.9M Q4 '19: -11.6M Q1 '20: -9.9M Q2 '20: -14M Q3 '20: -16.1M Q4 '20: -17M Q1 '21: -15.3M Q2 '21: -21.5M Q3 '21: -9.6M Q4 '21: -15.1M Q1 '22: -7.8M Q2 '22: -8.2M Q3 '22: -6.1M Q4 '22: -7.1M Q1 '23: -9.4M Q2 '23: -7M Q3 '23: -6.4M Q4 '23: -7.4M Q1 '24: -1.9M Q2 '24: -1.7M Q3 '24: -781K Q4 '24: -592K Q1 '25: -772K Q2 '25: -701K Q3 '25: -844K Q4 '25: -552K Q1 '26: -1M Q2 '26: -300K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-40M -20M 0 20M 40M 60M Q1 '15: -9.7M Q2 '15: -11.7M Q3 '15: 45.2M Q4 '15: -24.2M Q1 '16: -16.2M Q2 '16: -15.2M Q3 '16: -14.3M Q4 '16: -13.1M Q1 '17: -14.6M Q2 '17: -15.6M Q3 '17: -12.8M Q4 '17: -12.4M Q1 '18: -19.1M Q2 '18: -10.4M Q3 '18: -8.7M Q1 '19: -10.2M Q2 '19: -8.2M Q3 '19: -11M Q4 '19: -11.7M Q1 '20: -10.4M Q2 '20: -17.5M Q3 '20: -18.1M Q4 '20: -20.8M Q1 '21: -16M Q2 '21: -23.3M Q3 '21: -9.9M Q4 '21: -15.5M Q1 '22: -7.8M Q2 '22: -8.2M Q3 '22: -6.2M Q4 '22: -7.2M Q1 '23: -9.4M Q2 '23: -7.1M Q3 '23: -6.4M Q4 '23: -7.4M Q1 '24: -1.9M Q2 '24: -1.7M Q3 '24: -781K Q4 '24: -592K Q4 '25: -553K Q1 '16 Q2 '17 Q3 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q3 '09: 21.8M Q2 '10: 48.8M Q3 '10: 47.4M Q2 '11: 67.2M Q3 '11: 68.1M Q2 '12: 78.5M Q3 '12: 78.7M Q2 '21: 214.4M Q3 '21: 214.5M Q1 '22: 214.9M Q2 '22: 215M Q3 '22: 215.1M Q1 '23: 16M Q2 '23: 1.6M Q3 '23: 1.6M Q1 '24: 1.6M Q2 '24: 1.6M Q3 '24: 1.6M Q1 '25: 1.6M Q2 '25: 1.7M Q3 '25: 2.2M Q1 '26: 1.9M Q2 '26: 2.4M Q2 '10 Q3 '11 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q3 '15: -1.03 Q2 '16: -1.31 Q3 '16: -1.28 Q2 '17: -0.50 Q3 '17: -0.52 Q4 '17: -0.53 Q1 '18: -0.53 Q2 '18: -0.52 Q3 '18: -0.52 Q4 '18: 0.89 Q1 '19: 0.96 Q2 '19: 0.99 Q3 '19: 0.69 Q4 '19: -0.69 Q1 '20: -0.70 Q2 '20: -0.70 Q3 '20: -0.37 Q4 '20: -0.39 Q1 '21: -0.40 Q2 '21: -0.42 Q3 '21: -0.43 Q4 '21: -0.38 Q1 '22: -0.33 Q2 '22: -0.27 Q3 '22: -0.20 Q4 '22: -2.62 Q1 '23: -3.20 Q2 '23: -8.64 Q3 '23: -13.90 Q4 '23: -16.32 Q1 '24: -16.74 Q2 '24: -11.96 Q3 '24: -7.36 Q4 '24: -2.92 Q1 '25: -2.54 Q2 '25: -2.46 Q3 '25: -2.31 Q4 '25: -2.21 Q1 '26: -2.13 Q2 '26: -1.91 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.